6505--Carvedilol Tablets (VA-25-00048048)

The Department of Veterans Affairs National Acquisition Center is seeking to establish a pharmaceutical prime vendor contract for Carvedilol Tablets across multiple strengths (3.125mg, 6.25mg, 12.5mg, and 25mg) in 100-tablet and 500-tablet bottle configurations. This solicitation (Number 36E79725R0028) requires offerors to submit comprehensive pricing for all line items and option years, including a 0.50% Cost Recovery Fee. Potential contractors must provide a unique 11-digit NDC number, submit a Letter of Commitment from the manufacturer if not the manufacturer directly, and demonstrate compliance with FDA current Good Manufacturing Practices (cGMP). The solicitation mandates that offerors meet specific technical and administrative requirements, with offers due by 2:30 PM on April 22, 2025. Evaluation criteria will likely focus on pricing, manufacturing capabilities, regulatory compliance, and the ability to meet the estimated annual usage requirements.

The contract is set aside for small businesses with a size standard of 1,300 employees and will have a base year with four one-year option periods. Estimated annual usage ranges from 3,592 to 154,712 bottles, serving multiple federal agencies including the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. McKesson Corporation is listed as a primary VA and DoD pharmaceutical prime vendor through which the contract will be distributed. The anticipated contract effective date is April 8, 2025, with an intended geographical coverage spanning multiple federal healthcare systems. Contractors will need to demonstrate the capacity to supply Carvedilol Tablets consistently across various federal healthcare facilities, with the ability to meet fluctuating demand across different tablet strengths and bottle configurations.